DOI: https://doi.org/10.26641/2307-0404.2013.2.15949

Genotype of cytochrome-450 2C9 in patients with tuberculosis

V. V. Filyuk, V. I. Kresyun, P. B. Antonenko, K. K. Rogach, Yu. M. Danylenko, G. V. Mozolevych

Abstract


The aim of present work was to investigate CYP2С9 polymorphism in the south of Ukraine in TB-patients and comparing with the same data of control group by the example of Odessa region. Gene CYP2С9 polymorphism was studied with the help of PCR (polymerase chain reaction) and endonuclease analysis. The blood samples were obtained from patients with new cases of pulmonary TB from Odessa regional antituberculous dispensary and healthy donors in Odessa district station of blood transfusion in the year 2010-12. According to genotype of CYP2C9 of 55 TB-patients, 67,3% persons were the carriers of  homozygote wild gene CYP2C9*1/*1, 21,8 and 3,6% - heterozygote genes CYP2C9*1/*2 and CYP2C9*1/*3. Only 7,2% individuals belonged to carriers of slow metabolizers genotype - CYP2C9*2/*2, *2/*3, *3/*3. In general, the mutated alleles CYP2C9*2 and CYP2C9*3 in TB-males were observed by 1,8 times more frequently than among healthy donors of the same gender. TB-patients older than 30 years more frequently had mutated allele CYP2C9*2, almost by 3 times than individuals from control group.

Keywords


CYP2C9 gene; polymorphism; genotype; tubercuosis

References


Антоненко П.Б. Поліморфізм генотипу цито-хрому -450 2С9 в Одеському регіоні / П.Б. Антоненко, В.Й. Кресюн // Актуальні проблеми сучасної меди-цини : Вісник Укр. медичної стомат. академії. - 2011. - Т. 11, вип. 4, ч. ІІ. - С. 51-55.

Кресюн В.И. Фармакогенетические основы взаимодействия организма и лекарств / В.И. Кресюн, Ю.И. Бажора. – Одесса: Одес. гос. мед. ун-т, 2007. – 164 с.

Cigarette Smoking, Genetic Variants in Carci-nogen-metabolizing Enzymes, and Colorectal Cancer Risk / Sean P. Cleary, Michelle Cotterchio, Ellen Shi, Steven Gallinger [et al.] // Am. J. Epidemiol. – 2010. – Vol. 172, N 9. – P. 1000–1014.

Genetic predisposition to acute gastrointestinal blee¬ding after NSAIDs use / Carmen Martínez, Gerardo Blanco, José M Ladero, Elena García-Martín [et al.] // Br. J. Phar¬macol. – 2004. – Vol. 141, N 2. – P. 205–208.

Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort / E. Haschke-Becher, J. Kirchheiner, O. Trum-mer, G. Grünbacher [et al.] // Pharmaco¬geno-mics. – 2010. – N 10. – P. 1359-1365.

Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis / J.D. Lindh, L. Holm, M.L. Andersson, A. Rane // Eur. J. Clin. Pharmacol. – 2009. – Vol. 65, N 4. – P. 365-375.

Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharma-cogenomics to predict efficacy in different ethnic popu-lations / T. Gumbo, A. Louie, W. Liu [et al.] // Antimic-robial Agents Chemotherapy. – 2007. – Vol. 51, N 7. - P. 2329–2336.

The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement / V. Tatarūnas, V. Lesauskaitė, A. Vei-kutienė [et al.] // Medicina. Kaunas. – 2011. – Vol. 47, N1. – P. 25-30.

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism / T.H. Sullivan-Klose, B.I. Gha¬nayem, D.A. Bell [et al.] // Pharmacogenetics. – 1996. – Vol. 6, N 4. – P. 341-349.

Substrates, inducers, inhibitors and structure-acti-vity relationships of human Cytochrome P450 2C9 and implications in drug development / S.F. Zhou, Z.W. Zhou, L.P. Yang, J.P. Cai // Curr. Med. Chem. – 2009. – Vol. 16, N 27. – P. 3480-3675.

Antonenko PB, Kresyun VY. PolImorfIzm geno-tipu tsitohromu -450 2S9 v Odeskomu regioni. Aktualni problemi suchasnoyi meditsini: Visnik Ukr. medichnoyi stomat. akademiyi. 2011;11(4):51-55.

Kresyun VI, Bazhora YuI. Farmakogeneticheskie osnovyi vzaimodeystviya organizma i lekarstv. Odessa: Odes gos med un-t. 2007;164.

Sean P Cleary, Michelle Cotterchio, Ellen Shi, Steven Gallinger. Cigarette Smoking, Genetic Variants in Carcinogen-metabolizing Enzymes and Colorectal Cancer Risk. Am J Epidemiol. 2010;172(9):1000–14.

Carmen Martínez, Gerardo Blanco, José M La-dero, Elena García-Martín Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol. 2004;141(2):205–8.

Haschke-Becher E, Kirchheiner J, Trummer O, Grünbacher G. Impact of CYP2C8 and 2C9 poly¬morp-hisms on coronary artery disease and myocardial in-farction in the LURIC cohort. Pharmacogenomics. 2010;10:1359-65.

Lindh JD, Holm L, Andersson ML, Rane A. In-fluence of CYP2C9 genotype on warfarin dose re-quirements--a systematic review and meta-analysis. Eur J Clin Pharmacol. 2009;65(4):365-75.

Gumbo T, Louie A, Liu W. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict ef¬ficacy in different ethnic populations. Antimicrobial Agents Chemotherapy. 2007;51(7):2329–36.

Tatarūnas V, Lesauskaitė V, Veikutienė A. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement. Medicina. Kaunas. 2011;47(1):25-30.

Sullivan-Klose TH, Ghanayem BI, Bell DA. The role of the CYP2C9-Leu359 allelic variant in the tol¬bu¬ta-mide polymorphism. Pharmacogenetics. 1996;6(4):341-9.

Zhou SF, Zhou ZW, Yang LP, Cai JP. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-3675.


GOST Style Citations


—




 

This work is licensed under a Creative Commons Attribution 4.0 International License